Infection Prevention and Control Implications of Special Pathogens in Children.
Ebola
High-consequence infectious diseases
Infection control
Infection prevention
Marburg
Mpox
Preparedness
Special pathogen
Journal
Pediatric clinics of North America
ISSN: 1557-8240
Titre abrégé: Pediatr Clin North Am
Pays: United States
ID NLM: 0401126
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
16
5
2024
Statut:
ppublish
Résumé
Special pathogens are broadly defined as highly transmissible organisms capable of causing severe disease in humans. Children's hospital healthcare personnel (HCP) should be prepared to identify patients possibly infected with a special pathogen, isolate the patient to minimize transmission, and inform key infection prevention, clinical, and public health stakeholders. Effective preparedness requires resources and practice with attention to education, policies and procedures, drills and training, and supplies. Successfully preparing for special pathogens is an important measure toward keeping communities, HCP, and patients and families safe in this global age that brings pathogens from across the world to our doorstep.
Identifiants
pubmed: 38754934
pii: S0031-3955(24)00025-7
doi: 10.1016/j.pcl.2024.01.014
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
431-454Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure L.K. Kociolek reports grant support from Merck, United States and the Department of Health and Human Services, United States, Health Resources and Services Administration, United States. A.L. Shane reports grant support from the Department of Health and Human Services, Administration for Strategic Preparedness and Response, United States (BARDA). K.A. Simonsen reports grant support from Merck, Alinta, and the Department of Health and Human Services, Administration for Strategic Preparedness and Response to support her salary. D.M. Zerr reports grant from Merck and consultancy for Allovir.